Previous investigations have demonstrated that patients with impaired glycemic indices, such as elevated levels of fasting blood glucose (FBS), fasting insulin (FI), and Homeostasis Model Assessment-Estimated Insulin Resistance (HOMA-IR), face an elevated risk of developing NAFLD [2, 14, 15]. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.